Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG58)Product type:GuidanceProgramme:Diagnostics guidancePublished: 9 May 2024
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 February 2024
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 September 2024
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 5 March 2025
Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)Status:In developmentProgramme:NICE guidelineExpected publication date: 31 March 2025
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 10 September 2025
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer ID 6200Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lymphoedema: prevention and management in people with early, locally advanced, and advanced breast cancer (update)Status:In developmentProgramme:NICE guidelineExpected publication date: TBC
Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer TS ID 11990Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Magtrace/Sentimag MT599 (MIB263)Status:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
Signatera molecular residual disease assay (MT741)Status:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
Larotrectinib for treating NTRK fusion-positive solid tumours (MA review of TA630) [ID6292]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC